Arcturus Therapeutics (ARCT) Receives Orphan Drug Designation From The U.S. FDA For ARCT-032, For The Treatment Of Cystic Fibrosis : Vimarsana.com

Arcturus Therapeutics (ARCT) Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis

Arcturus Therapeutics (ARCT) Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Joseph Payne , Arcturus Therapeutics Holdings Inc , Drug Designation For The Company , Office Of Orphan Products Development , Drug Administration , Nasdaq , Arcturus Therapeutics Holdings , Orphan Drug Designation , Orphan Products Development , Prescription Drug User Fee Act Application , Drug Designation , Chief Executive Officer ,

vimarsana.com © 2020. All Rights Reserved.